Short answer
Pediatrix Medical Group, Inc. (MD) filed its fiscal 2025 10-K annual report with the SEC on Feb 19, 2026. It reported revenue of $1.9B (−4.9% year over year) and net income of $165M.
- Top risk flagged: Regulatory/legal risk: potential audit, inquiry, or investigation impact on revenue from government agencies over $1.15B gross receivables and DSO 42.8 days
FY2025 key financial metrics · XBRL
- Revenue
- $1.9B
- −4.9% YoY
- Net income
- $165M
- +266.9% YoY
- Operating margin
- 10.9%
- +14.3 pp YoY
- EPS (diluted)
- $1.94
- +263.0% YoY
- ROE
- 19.1%
- +32.1 pp YoY
- Operating cash flow
- $271M
- +31.2% YoY
Source: XBRL data from the Pediatrix Medical Group, Inc. (MD) FY2025 10-K on SEC EDGAR. USD.
Pediatrix Medical Group, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: provider of neonatal and pediatric healthcare services
- No new products, services, or segments introduced or emphasized this year
- No stated strategic shift or changed competitive positioning vs prior year
- 144 holders of record of common stock as of February 13, 2026; stock price $21.52 per share
- No dividends declared or paid in 2023-2025; dividend payments limited by credit agreement
Management Discussion & Analysis
- Profitability or margin changes not specified in provided text
- Segment details: 1,350 neonatal physicians, 475 maternal-fetal, 230 pediatric intensive care, 220 hospital-based pediatric, 20 pediatric surgical
- No cash flow, buybacks, dividends, or capex info given
- Risks: potential revenue impact from shifts toward government healthcare programs due to economic/demographic changes and rising bad debt from patient payment difficulties
Risk Factors
- Regulatory/legal risk: potential audit, inquiry, or investigation impact on revenue from government agencies over $1.15B gross receivables and DSO 42.8 days
- Geopolitical/macro risk: 32% of net revenue concentrated in Texas exposing Pediatrix to regional health policy or economic shifts
- Operational/supply chain risk: transformation and restructuring expenses $22.3M in 2025 due to shared services position eliminations and revenue cycle transitions
- Competitive/market disruption risk: practice dispositions reducing net revenue by $99.1M or 4.9% in 2025, affecting market footprint and growth
- Financial/structural risk: goodwill impairment charge of $150.6M in 2024 reflecting valuation sensitivity to market capitalization and stock price declines
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.